Genetic profile predicts response to infliximab treatment for ra

Access through your institution Buy or subscribe Lequerré T _ et al_. (2006) Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. _Arthritis Res

Ther_ 8: R105 Between 20% and 40% of patients with rheumatoid arthritis (RA) who receive therapy with methotrexate and a tumor necrosis factor inhibitor (such as infliximab) do not respond

to treatment. As the prognostic markers usually used in RA cannot predict patient responses to this therapy, some researchers have turned to genetic profiling. Lequerré and colleagues have

now identified two sets of transcripts that can reliably predict patient response to methotrexate–infliximab treatment. This is a preview of subscription content, access via your institution

ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article *

Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn

about institutional subscriptions * Read our FAQs * Contact customer support RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Genetic profile predicts

response to infliximab treatment for RA. _Nat Rev Rheumatol_ 2, 524–525 (2006). https://doi.org/10.1038/ncprheum0284 Download citation * Issue Date: October 2006 * DOI:

https://doi.org/10.1038/ncprheum0284 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative